...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR 2019

AACR 2019, March 29 to April 3, 2019 in Atlanta, Georgia. Clinical Trial and Late-Breaking Abstract Titles Posted to Online Itinerary Planner today. Poster session April 1. No abstract available yet.

CT095. A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

 


Feb 28, 2019 06:30AM
3
Feb 28, 2019 08:33AM
3
Feb 28, 2019 10:18AM
1
Feb 28, 2019 11:26AM
2
Feb 28, 2019 11:39AM
2
Feb 28, 2019 11:46AM
1
Feb 28, 2019 11:46AM
3
Feb 28, 2019 01:48PM
7
Feb 28, 2019 02:07PM
Share
New Message
Please login to post a reply